company background image
ADAG

Adagene NasdaqGM:ADAG Stock Report

Last Price

US$1.14

Market Cap

US$49.5m

7D

14.0%

1Y

-85.3%

Updated

04 Dec, 2022

Data

Company Financials +
ADAG fundamental analysis
Snowflake Score
Valuation3/6
Future Growth2/6
Past Performance0/6
Financial Health3/6
Dividends0/6

ADAG Stock Overview

Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers.

Adagene Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Adagene
Historical stock prices
Current Share PriceUS$1.14
52 Week HighUS$10.88
52 Week LowUS$0.90
Beta0
1 Month Change19.11%
3 Month Change-25.00%
1 Year Change-85.33%
3 Year Changen/a
5 Year Changen/a
Change since IPO-96.20%

Recent News & Updates

The Consensus EPS Estimates For Adagene Inc. (NASDAQ:ADAG) Just Fell Dramatically

Oct 05
The Consensus EPS Estimates For Adagene Inc. (NASDAQ:ADAG) Just Fell Dramatically

Recent updates

The Consensus EPS Estimates For Adagene Inc. (NASDAQ:ADAG) Just Fell Dramatically

Oct 05
The Consensus EPS Estimates For Adagene Inc. (NASDAQ:ADAG) Just Fell Dramatically

Shareholder Returns

ADAGUS BiotechsUS Market
7D14.0%4.2%1.5%
1Y-85.3%-7.4%-14.9%

Return vs Industry: ADAG underperformed the US Biotechs industry which returned -7.4% over the past year.

Return vs Market: ADAG underperformed the US Market which returned -14.9% over the past year.

Price Volatility

Is ADAG's price volatile compared to industry and market?
ADAG volatility
ADAG Average Weekly Movement11.0%
Biotechs Industry Average Movement11.2%
Market Average Movement7.4%
10% most volatile stocks in US Market15.7%
10% least volatile stocks in US Market3.3%

Stable Share Price: ADAG is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: ADAG's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2011259Peizhi Luohttps://www.adagene.com

Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company’s product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of advanced metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody, which is in preclinical; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical stage for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody, which is in preclinical stage for the treatment off-tumor toxicities.

Adagene Inc. Fundamentals Summary

How do Adagene's earnings and revenue compare to its market cap?
ADAG fundamental statistics
Market CapUS$49.50m
Earnings (TTM)-US$83.63m
Revenue (TTM)US$12.74m

3.9x

P/S Ratio

-0.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ADAG income statement (TTM)
RevenueUS$12.74m
Cost of RevenueUS$0
Gross ProfitUS$12.74m
Other ExpensesUS$96.37m
Earnings-US$83.63m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-1.93
Gross Margin100.00%
Net Profit Margin-656.46%
Debt/Equity Ratio14.7%

How did ADAG perform over the long term?

See historical performance and comparison